Arterial Thrombosis
10
2
2
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
Intra-arterial Thrombolysis After Successful Thrombectomy for Acute Ischemic Stroke in the Posterior Circulation (IAT-TOP)
JETi Lower Extremity Arterial Thrombosis
Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer
PeriOperative ISchemic Evaluation-3 Trial
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus
Arterial Thrombosis and Inflammatory Bowel Disease: a Series of 6 Cases and Literature Review